SCHEMBL1009317

SCHEMBL1009317

O=c1[nH]ncc(Cc2ccccc2C(F)(F)F)c1Cl

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 7/20 0.54
KCNH2 Q12809 1/20 0.54
TRPC4 Q9UBN4 1/20 0.54
AR P10275 1/20 0.51
AKR1B1 P15121 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
DAO P14920 1/20 0.40
PKM P14618 1/20 0.39
TRPA1 O75762 2/20 0.39
TIPARP Q7Z3E1 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
AXL P30530 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009123 0.73 AR (0.49) TRPC5KCNH2TRPC4ARAKR1B1
SCHEMBL20832175 0.73 TRPC5 (0.76) TRPC5KCNH2TRPC4TIPARPALDH1A1
SCHEMBL24176690 0.73 TRPC5 (0.65) TRPC5KCNH2TRPC4ALDH1A1
SCHEMBL24176691 0.73 TRPC5 (0.65) TRPC5KCNH2TRPC4ALDH1A1
SCHEMBL1009667 0.72 TRPC5 (0.43) TRPC5KCNH2TRPC4PKMTRPA1
SCHEMBL24176723 0.72 TRPC5 (0.64) TRPC5KCNH2TRPC4TIPARPALDH1A1
SCHEMBL20818433 0.71 TRPC5 (0.50) TRPC5KCNH2TRPC4MKNK1MKNK2
SCHEMBL20818378 0.71 TRPC5 (0.64) TRPC5KCNH2TRPC4AKR1B1TIPARP
SCHEMBL20818043 0.71 TRPC5 (1.00) TRPC5KCNH2TRPC4ALDH1A1
SCHEMBL20831710 0.71 TRPC5 (0.61) TRPC5KCNH2TRPC4TIPARPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
CN-102007116-A Pyridazinone glucokinase activators HOFFMANN LA ROCHE 2011-04-06 CN disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK TRPC5 3891/4885KCNH2 1074/4885TRPC4 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.